PanGen Biotech Inc
PanGen Biotech Inc. operates as a biologics company in South Korea. It develops biosimilar products, such as EPO, recombinant factor VIII, G-CSF, etc. The company also provides CHO cell lines for proteins and monoclonal antibodies; and one-stop services ranging from producer cell line development to GMP production. In addition, it offers reagents, quantitation kits, and cell based assay systems, … Read more
PanGen Biotech Inc (222110) - Total Liabilities
Latest total liabilities as of September 2025: ₩2.74 Billion KRW
Based on the latest financial reports, PanGen Biotech Inc (222110) has total liabilities worth ₩2.74 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
PanGen Biotech Inc - Total Liabilities Trend (2014–2024)
This chart illustrates how PanGen Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
PanGen Biotech Inc Competitors by Total Liabilities
The table below lists competitors of PanGen Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cohiba Minerals Limited
PINK:CHKMF
|
USA | $167.00K |
|
PT Intra GolfLink Resorts Tbk
JK:GOLF
|
Indonesia | Rp703.87 Billion |
|
Laseroptek Co., Ltd.
KQ:199550
|
Korea | ₩15.44 Billion |
|
Prizma Pres Matbaacilik Yayincilik Sanayi ve Ticaret AS
IS:PRZMA
|
Turkey | TL7.55 Million |
|
Nido Education Ltd
AU:NDO
|
Australia | AU$213.70 Million |
|
Arizona Silver Exploration Inc
OTCQB:AZASF
|
USA | $266.83K |
|
Nippon Indosari Corpindo Tbk
JK:ROTI
|
Indonesia | Rp1.79 Trillion |
Liability Composition Analysis (2014–2024)
This chart breaks down PanGen Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PanGen Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PanGen Biotech Inc (2014–2024)
The table below shows the annual total liabilities of PanGen Biotech Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩5.64 Billion | -31.06% |
| 2023-12-31 | ₩8.18 Billion | +136.67% |
| 2022-12-31 | ₩3.45 Billion | -84.43% |
| 2021-12-31 | ₩22.18 Billion | +0.37% |
| 2020-12-31 | ₩22.10 Billion | +6.98% |
| 2019-12-31 | ₩20.66 Billion | +10.65% |
| 2018-12-31 | ₩18.67 Billion | +335.84% |
| 2017-12-31 | ₩4.28 Billion | +104.76% |
| 2016-12-31 | ₩2.09 Billion | -77.60% |
| 2015-12-31 | ₩9.34 Billion | +50.99% |
| 2014-12-31 | ₩6.18 Billion | -- |